Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−11.75 USD
−58.77 M USD
0.00 USD
8.55 M
About Kalaris Therapeutics, Inc.
Sector
Industry
CEO
Andrew Oxtoby
Website
Headquarters
Palo Alto
FIGI
BBG00P80SH34
Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. It is focusing on developing TH103, a novel anti-VEGF agent targeted at treating neovascular and exudative retinal diseases. The company is headquartered in Palo Alto, CA.
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Related stocks
Frequently Asked Questions
The current price of KLRS is 8.82 USD — it has decreased by −8.29% in the past 24 hours. Watch Kalaris Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Kalaris Therapeutics, Inc. stocks are traded under the ticker KLRS.
KLRS stock has risen by 0.84% compared to the previous week, the month change is a −3.41% fall, over the last year Kalaris Therapeutics, Inc. has showed a −97.79% decrease.
KLRS reached its all-time high on Dec 23, 2020 with the price of 25,899.84 USD, and its all-time low was 7.96 USD and was reached on Jan 16, 2025. View more price dynamics on KLRS chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
KLRS stock is 25.90% volatile and has beta coefficient of −0.46. Track Kalaris Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Kalaris Therapeutics, Inc. there?
Today Kalaris Therapeutics, Inc. has the market capitalization of 196.38 M, it has increased by 583.77% over the last week.
Yes, you can track Kalaris Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Kalaris Therapeutics, Inc. is going to release the next earnings report on May 1, 2025. Keep track of upcoming events with our Earnings Calendar.
KLRS net income for the last quarter is −18.27 M USD, while the quarter before that showed −4.13 M USD of net income which accounts for −342.75% change. Track more Kalaris Therapeutics, Inc. financial stats to get the full picture.
No, KLRS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Mar 25, 2025, the company has 6.00 employees. See our rating of the largest employees — is Kalaris Therapeutics, Inc. on this list?
Like other stocks, KLRS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Kalaris Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Kalaris Therapeutics, Inc. technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Kalaris Therapeutics, Inc. stock shows the sell signal. See more of Kalaris Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.